BLA 103293 · Chiron
Proleukin
Aldesleukin · Lymphocyte Growth Factor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Sep 29, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
May 5, 1992
Approved uses
3
Original approval plus efficacy supplements
Registered trials
528
39 Phase 3, 38 recruiting
FAERS reports
1,262
1,172 serious, 211 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CAPILLARY LEAK SYNDROME (CLS), NEUROLOGIC TOXICITIES and SERIOUS INFECTIONS Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4) , Contraindications (4) , Warnings and Precautions (5.1) ] . Neurologic toxicities, which may be life-threatening or result in coma or permanent neurological deficits, have occurred in patients treated with Proleukin. Withhold or discontinue Proleukin as recommended [see Dosage and Administration (2.4) , Warnings and Precautions (5.2) ] . Serious Infections including sepsis and bacterial endocarditis have occurred...
What it is approved for
From the label in effect Dec 20, 2024.
Proleukin is a lymphocyte growth factor indicated for: The treatment of adults with metastatic renal cell carcinoma. ( 1.1 ) The treatment of adults with metastatic melanoma. ( 1.2 ) 1.1 Metastatic Renal Cell Carcinoma Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC). 1.2 Metastatic Melanoma Proleukin is indicated for the treatment of adults with metastatic melanoma.
Mechanism: Aldesleukin is an interleukin-2 lymphocyte growth factor. The antitumor activity of aldesleukin has not been fully characterized. In vitro studies performed on human cell lines show enhancement of lymphocyte mitogenesis and cytotoxicity, induction of killer cell activity [lymphokine-activated killer (LAK) and natural killer (NK) cells] and interferon gamma production, and proliferation of human interleukin-2-dependent cell lines. Administration of aldesleukin in animals and humans produces multiple immunological effects in a dose-dependent manner. These effects include activation of cellular...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 9, 1998 Supplement 1019 · Efficacy
- Jan 9, 1998 Supplement 1021 · Efficacy · priority review ReviewLetter
- May 5, 1992 Original approval · Type 1 - New Molecular Entity
1 products under this application
- PROLEUKIN · ALDESLEUKIN 22MIU/VIAL · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aldesleukin" as an intervention, any sponsor and status, largest first.
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00004978 · 4,150 participants · Start Mar 2000 · Primary completion Nov 2008
Drug: Recombinant interleukin-2 (rIL-2) · For: HIV Infections
Sites: Los Angeles, California; Mill Valley, California; Oakland, California · 248 sites in all
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00004128 · 2,000 participants (planned) · Start Sep 1999 · Primary completion Jan 2008
Drug: aldesleukin; filgrastim and 5 more · For: Leukemia
- Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)Pivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT00013611 · 1,695 participants · Start Mar 2001 · Primary completion Jan 2007
Drug: Proleukin · For: HIV Infection
Sites: Bethesda, Maryland
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00338377 · 1,230 participants · Start Feb 1, 2006 · Primary completion Feb 28, 2030
Drug: Dendritic Cell Immunization; Cyclophosphamide and 6 more · For: Melanoma
Sites: Houston, Texas
- Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic SyndromePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00002798 · 880 participants · Start Aug 1996 · Primary completion Sep 2006
Drug: asparaginase; daunorubicin hydrochloride and 12 more · For: Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Monoblastic Leukemia (M5a) and 13 more
Sites: Arcadia, California
- Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00006363 · 720 participants · Start Nov 2000 · Primary completion Jun 2005
Drug: cytarabine; daunorubicin hydrochloride and 5 more · For: Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Erythroid Leukemia (M6) and 30 more
Sites: Chicago, Illinois
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia153
- hypotension112
- off label use107
- thrombocytopenia84
- diarrhoea82
- vomiting71
- nausea69
- fatigue67
- chills65
- dyspnoea65
- febrile neutropenia64
- pain62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 103 |
| 2006 | 48 |
| 2007 | 54 |
| 2008 | 55 |
| 2009 | 41 |
| 2010 | 42 |
| 2011 | 49 |
| 2012 | 35 |
| 2013 | 28 |
| 2014 | 12 |
| 2015 | 20 |
| 2016 | 24 |
| 2017 | 51 |
| 2018 | 12 |
| 2019 | 41 |
| 2020 | 68 |
| 2021 | 72 |
| 2022 | 44 |
| 2023 | 56 |
| 2024 | 111 |
| 2025 | 130 |
| 2026 | 74 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma.
Brown CE, Rodriguez A, Palmer J, et al. · Neuro Oncol 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
Zhao TX, Sriranjan RS, Tuong ZK, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial.
Lou E, Choudhry MS, Starr TK, et al. · Lancet Oncol 2025 · Clinical Trial, Phase I
- High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Fisher RI, Rosenberg SA, Sznol M, et al. · Cancer J Sci Am 1997 · Clinical Trial, Clinical Trial, Phase II
- A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.
Stevanovik S, Helman SR, Wunderlich JR, et al. · Clin Cancer Res 2019 · Clinical Trial, Phase II, Research Support, N.I.H., Intramural
- Engineering cytokines for cancer immunotherapy: a systematic review.
Fu Y, Tang R, Zhao X · Front Immunol 2023 · Systematic Review
Sponsor: Chiron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.